Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
101 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT03900598 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 226 | Janssen Research & Development, LLCINDUSTRY | 12 | Jun 22, 2025 |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT06143527 | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS | recruiting | Phase 1 | 20 | The Foundation for Orthopaedics and Regenerative MedicineOTHER | 2 | Apr 8, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation(Argonaut) | terminated | Phase 1 | 28 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 7 | Dec 12, 2024 | clinicaltrials |
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT04274738 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 2 | Aug 27, 2024 | clinicaltrials |
| NCT02400242 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | terminated | Phase 1 | 85 | CelgeneINDUSTRY | 5 | Jul 9, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma(BelaRd) | active not recruiting | Phase 1 / Phase 2 | 66 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT03489525 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma(MEDI2228) | completed | Phase 1 | 107 | MedImmune LLCINDUSTRY | 4 | Mar 28, 2022 | clinicaltrials |
| NCT04115956 | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | terminated | Phase 1 | 6 | Oncopeptides ABINDUSTRY | 9 | Mar 28, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT02626000 | Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)(MASTERKEY232) | completed | Phase 1 | 36 | AmgenINDUSTRY | 11 | Sep 8, 2021 | clinicaltrials |
| NCT00981708 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | completed | Phase 1 / Phase 2 | 37 | University of AthensOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02626234 | A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors | completed | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT02244632 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | completed | Phase 1 / Phase 2 | 105 | Isofol Medical ABINDUSTRY | 4 | Sep 9, 2020 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT02289196 | Safety Study of Vx006 Vaccine in Solid Tumor Patients | completed | Phase 1 | 23 | Vaxon BiotechINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01767623 | A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants | completed | Phase 1 | 8 | Hoffmann-La RocheINDUSTRY | 7 | Feb 13, 2018 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT01851824 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 9 | Nov 2, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT00691379 | Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 46 | Hellenic Oncology Research GroupOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01716546 | Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer | terminated | Phase 1 / Phase 2 | 51 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT02175381 | Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 69 | Hellenic Oncology Research GroupOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00423124 | Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies | completed | Phase 1 / Phase 2 | 57 | AGC Biologics S.p.A.INDUSTRY | 5 | May 30, 2014 | clinicaltrials |
| NCT00297089 | A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 165 | AbbVie (prior sponsor, Abbott)INDUSTRY | 6 | Jan 31, 2013 | clinicaltrials |
| NCT00002904 | Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors | completed | Phase 1 | 40 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Jul 2, 2012 | clinicaltrials |
| NCT00003028 | MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 5 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Jul 2, 2012 | clinicaltrials |
| NCT00429559 | Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma | completed | Phase 1 / Phase 2 | 31 | Hellenic Oncology Research GroupOTHER | 1 | Jul 22, 2011 | clinicaltrials |
| NCT00750386 | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | completed | Phase 1 / Phase 2 | 50 | Hellenic Oncology Research GroupOTHER | 1 | May 23, 2011 | clinicaltrials |
| NCT00705315 | Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 46 | Hellenic Oncology Research GroupOTHER | 1 | Aug 19, 2010 | clinicaltrials |
| NCT00684099 | Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 70 | Hellenic Oncology Research GroupOTHER | 1 | Dec 15, 2009 | clinicaltrials |
| NCT00706069 | Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer | completed | Phase 1 | 40 | Hellenic Oncology Research GroupOTHER | 1 | Dec 15, 2009 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials